Development and Assessment of a Septuple-Deletion Mutant Live Attenuated Vaccine for Actinobacillus pleuropneumoniae in Swine

被引：0
作者：
Cao, Weiwei [1 ]
He, Qiyun [1 ]
Chen, Yunpeng [1 ]
Liu, Jiahui [1 ]
Wei, Zudan [1 ]
Wei, Xinchen [1 ]
Chen, Huanchun [1 ]
Bei, Weicheng [1 ,2 ]
机构：
[1] Huazhong Agr Univ, Coll Vet Med, Cooperat Innovat Ctr Sustainable Pig Prod, Natl Key Lab Agr Microbiol, Wuhan, Peoples R China
[2] Hubei Hongshan Lab, Wuhan, Peoples R China
来源：
PAKISTAN VETERINARY JOURNAL | 2024年 / 44卷 / 04期
基金：
中国国家自然科学基金;
关键词：
Actinobacillus; Porcine pleuropneumonia; Attenuated vaccine; Mutant strain; SLW08; APX TOXINS; VIRULENCE; IMMUNOGENICITY; DETERMINANT; RESISTANCE;
D O I：
10.29261/pakvetj/2024.297
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
Actinobacillus pleuropneumoniae (APP) is a respiratory pathogen which causes severe pleuropneumonia in swine, leading to substantial economic losses in the pig industry. Current vaccines have shown limited protection against APP. The present study aimed to develop and evaluate a septuple-deletion mutant strain of APP (SLW08; serovar 1) as a live attenuated vaccine candidate. The SLW08 was developed from the sextuple-deletion mutant APP WBY06 (Delta apxIC Delta apxIIC Delta orf1 Delta cpxAR Delta arcA Delta ureA) by knocking out ApxIVA and inserting ApxIIIA into the ApxIVA locus. The virulence of mutant strain was assessed in mice. The immunogenicity, safety, and protective efficacy of SLW08 were evaluated in mice and piglets. Protection studies involved challenging immunized and control animals with a virulent APP strain (SLW01) and vaccine efficacy was determined using survival rates and lung pathology. The SLW08 strain exhibited slower growth rates as compared to the WBY06 and WT (SLW01) strains but showed significantly reduced virulence. Vaccinated pigs demonstrated strong immune responses without adverse effects. Upon challenge with virulent APP, the vaccinated pigs showed markedly reduced signs of infection compared to controls, indicating strong protective efficacy. SLW08, expressing ApxIII, provided effective protection to mice and piglets against APP, with less toxicity, resulting in higher survival rates and less lung pathology. The SLW08 mutant of APP with strong immune responses may represent a promising live attenuated vaccine candidate for protecting swine against APP infection.
引用
收藏
页码：1229 / 1236
页数：8
相关论文
共 35 条
  • [1] Augustyniak A, Pomorska-Mol M, Vaccination failures in pigs—the impact of chosen factors on the immunisation efficacy, Vaccine, 11, 2, (2023)
  • [2] Bao C, Jiang H, Zhu R, Et al., Differences in pig respiratory tract and peripheral blood immune responses to Actinobacillus pleuropneumoniae, Vet Microbiol, 247, (2020)
  • [3] Bei W, He Q, Yan L, Et al., Construction and characterization of a live, attenuated ApxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker, FEMS Microbiol Lett, 243, 1, pp. 21-27, (2005)
  • [4] Bosse JT, Janson H, Sheehan BJ, Et al., Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection, Microbes Infect, 4, 2, pp. 225-235, (2002)
  • [5] Bosse JT, Li Y, Atherton TG, Et al., Characterisation of a mobilisable plasmid conferring florfenicol and chloramphenicol resistance in Actinobacillus pleuropneumoniae, Vet Microbiol, 178, 3-4, pp. 279-282, (2015)
  • [6] Chiang CH, Huang WF, Huang LP, Et al., Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model, Vaccine, 27, 34, pp. 4565-4570, (2009)
  • [7] Chuekwon K, Cheng LT, Immune response to the dual antigen vaccine of Actinobacillus pleuropneumoniae in a mouse model, Trends Sci, 20, 11, (2023)
  • [8] Derevyanko MM, Ayshpur OE, Preclinical and clinical trials of a new Ukrainian inactivated vaccine against actinobacillary pleuropneumonia in pigs, Theor Appl Vet Med, 11, 1, pp. 3-7, (2023)
  • [9] Gimenez-Lirola LG, Jiang YH, Sun D, Et al., Simultaneous detection of antibodies against Apx toxins ApxI, ApxII, ApxIII, and ApxIV in pigs with known and unknown Actinobacillus pleuropneumoniae exposure using a multiplexing liquid array platform, Clin Vaccine Immunol, 21, 1, pp. 85-95, (2014)
  • [10] He Q, Zheng Y, Yan K, Et al., The cAMP receptor protein gene contributes to growth, stress resistance, and colonization of Actinobacillus pleuropneumoniae, Vet Microbiol, 290, (2024)
1234